Mouse Saa3 Stable Cell Line - NIH/3T3

The Serum Amyloid A3 (Saa3) gene encodes a key member of the murine acute-phase serum amyloid A family, playing a pivotal role in the innate immune system and systemic inflammatory responses. Unlike the Saa1 and Saa2 isoforms—which are predominantly expressed in the liver—Saa3 is significantly expressed in a variety of extrahepatic tissues, including adipose tissue, macrophages, the lungs, and the gastrointestinal tract. Under normal physiological conditions, the basal expression level of Saa3 is relatively low; however, upon stimulation by pro-inflammatory cytokines, tissue injury, bacterial endotoxins, or metabolic stress, its expression levels undergo a dramatic and rapid upregulation. As an acute-phase reactant and a multifunctional signaling molecule, the Saa3 protein exerts its effects through multiple receptor pathways—most notably via the Toll-like receptor 4 (TLR4) pathway—thereby amplifying inflammatory cascades and recruiting immune cells to sites of injury. Recent molecular biology studies have strongly indicated that the Saa3 gene is intimately involved in the pathogenesis of various acute and chronic diseases, such as obesity-associated insulin resistance, metabolic syndrome, and atherosclerosis, and may even facilitate the formation of metastatic microenvironments in certain types of cancer.

The murine Saa3 stable cell line, established within an NIH/3T3 cellular background, provides a highly valuable and consistent in vitro research tool designed to assist researchers in comprehensively exploring the functions of the Saa3 protein. NIH/3T3 is a well-established and robust murine embryonic fibroblast cell line; characterized by its rapid proliferation rate and well-defined genetic background, it offers an excellent cellular environment for the stable integration of genes and the expression of exogenous proteins. This specially engineered stable cell line is capable of constitutively expressing the murine Saa3 gene, thereby eliminating the need for tedious and time-consuming repetitive transient transfections while ensuring reproducible, high-level protein expression across multiple passages. Researchers frequently utilize these Saa3-expressing NIH/3T3 cells to dissect the complex intracellular signaling pathways triggered by Saa3—such as the activation of NF-κB and its subsequent mediation of downstream inflammatory mediator transcription. Furthermore, this stable cell line serves as a robust platform for conducting high-throughput pharmacological screening experiments, aiming to identify novel therapeutic compounds capable of inhibiting Saa3 expression or blocking its interaction with specific cellular receptors, thereby offering potential therapeutic strategies for chronic inflammatory and metabolic diseases.